COX-2 - Selective NSAIDs

American Journal of Nursing

Volumn 104, Issue 3, 2004, Pages 52-55

  Hutchison, Rob ^a,b  

^a PRESBYTERIAN HOSPITAL OF DALLAS   (United States)

^b TEXAS TECH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

ARTHRITIS; BONE REGENERATION; CHEMICALLY INDUCED DISORDER; COLON POLYPOSIS; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; DYSMENORRHEA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; ISCHEMIA; KIDNEY; PAIN; PATIENT SELECTION; REVIEW; RISK FACTOR; THROMBOCYTE AGGREGATION; VASCULARIZATION;

ADENOMATOUS POLYPOSIS COLI; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; BONE REGENERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DYSMENORRHEA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERTENSION; ISCHEMIA; ISOENZYMES; KIDNEY; MEMBRANE PROTEINS; PAIN; PATIENT SELECTION; PLATELET AGGREGATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK FACTORS;

EID: 2342471331     PISSN: 0002936X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000446-200403000-00021     Document Type: Review

References (28)

1. Leese PT, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000;40(2):124-32.
2. Wolfe MM, et al. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340(24):1888-99.
3. Simon LS, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282(20):1921-8.
4. Barden J, et al. Oral valdecoxib and injected parecoxib for acute postoperative pain: a quantitative systematic review. BMC Anesthesiol 2003;3(1):1.
5. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998;51:8-16.
6. Langman MJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282(20):1929-33.
7. Schafer AI. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995;35(3):209-19.
8. Reuben SS, Connelly NR. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesth Analg 2000;91(5):1221-5.
9. Reuben SS, et al. Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty. J Arthroplasty 2002;17(1):26-31.
10. Reicin AS, et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 2002;89(2):204-9.
11. Catella-Lawson F, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345(25):1809-17.
12. Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 2003;253(6):643-52.
13. Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003;325(6):349-62.
14. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 2003;138(11):917-24.
15. Zhang X, et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002;109(11):1405-15.
16. Simon AM, et al. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002;17(6):963-76.
17. Einhorn T. Use of COX-2 inhibitors in patients with fractures. American Academy of Orthopedic Surgeons Bulletin 2002;50(5):1-3.
18. Glassman SD, et al. The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine 1998;23(7):834-8.
19. Day R, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs. ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med 2000;160(12):1781-7.
20. Saag K, et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6 week controlled clinical trial. Arthritis Rheum 1998;41(9 Suppl):984.
21. Kivitz A, et al. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002;51(6):530-7.
22. The management of persistent pain in older persons. J Am Geriatr Soc 2002;50(6 Suppl):S205-24.
23. Daniels SE, et al. The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. J Am Dent Assoc 2002;133(5):611-21; quiz 25.
24. Daniels SE, et al. Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet Gynecol 2002;100(2):350-8.
25. Martin-Garcia C, et al. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002;121(6):1812-7.
26. Woessner KM, et al. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 2002;46(8):2201-6.
27. Szczeklik A, et al. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001;31(2):219-25.
28. Cribb AE, et al. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 1996;15(1):9-50.